Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

1.2K
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.2K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.2K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

7.7K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
7.7K
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

1.3K
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
1.3K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial.

Journal of psychiatric research·2022
Same author

Psychometric properties of the Generalized Anxiety Disorder 7-item scale in youth: Screening in a primary care sample.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2021
Same author

Pilot Studies to Evaluate Feasibility of a Physical Activity Intervention for Persons With Depression.

Journal of sport & exercise psychology·2020
Same author

Addressing adherence to antidepressant treatment for depression.

Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)·2020
Same author

Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography.

Nature biomedical engineering·2020
Same author

Two Trajectories of Depressive Symptom Reduction Throughout Behavioral Activation Teletherapy Among Underserved, Ethnically Diverse, Primary Care Patients: A VitalSign<sup>6</sup> Report.

Behavior therapy·2020

Related Experiment Video

Updated: Apr 20, 2026

Orienteering as a Tool for Cognitive Research: An Implementation Guide
07:13

Orienteering as a Tool for Cognitive Research: An Implementation Guide

Published on: November 29, 2024

1.8K

Dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the TREAD

Tracy L Greer1, Bruce D Grannemann1, Matthieu Chansard1

  • 1Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX 75390-9119, USA.

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|December 3, 2014
PubMed
Summary
This summary is machine-generated.

Exercise may improve cognitive function in major depressive disorder (MDD) patients. A higher exercise dose showed benefits for executive function and working memory, while some cognitive improvements occurred regardless of exercise intensity.

Keywords:
Cognitive impairmentsExecutive functionNeurocognitionPhysical activitySSRI partial responseWorking memory

More Related Videos

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.7K
Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
10:19

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease

Published on: August 22, 2014

14.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Orienteering as a Tool for Cognitive Research: An Implementation Guide
07:13

Orienteering as a Tool for Cognitive Research: An Implementation Guide

Published on: November 29, 2024

1.8K
Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression
04:33

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

1.7K
Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease
10:19

Getting to Compliance in Forced Exercise in Rodents: A Critical Standard to Evaluate Exercise Impact in Aging-related Disorders and Disease

Published on: August 22, 2014

14.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Exercise Science

Background:

  • Major depressive disorder (MDD) is associated with significant cognitive dysfunction, impacting attention, learning, memory, and executive functions.
  • Exercise interventions have demonstrated cognitive benefits in other populations but remain under-investigated as an augmentation strategy for depression.
  • Cognitive complaints are common in MDD patients, even after initial treatment with selective serotonin reuptake inhibitors (SSRIs).

Purpose of the Study:

  • To evaluate the effectiveness of exercise augmentation on cognitive performance in individuals with MDD and residual cognitive symptoms.
  • To investigate potential dose-response effects of exercise on specific cognitive domains in this population.
  • To determine if exercise can improve cognitive function in patients partially responding to SSRI treatment.

Main Methods:

  • The study analyzed data from 39 participants in the Treatment with Exercise Augmentation for Depression (TREAD) study.
  • Participants were randomized to either a low or high dose exercise regimen.
  • Cognitive performance was assessed using the Cambridge Neuropsychological Test Automated Battery (CANTAB) at baseline and 12 weeks, focusing on attention, memory, and executive functions.

Main Results:

  • A significant interaction effect was observed for the Executive Function/Set-shifting and Working Memory domain.
  • High-dose exercisers showed improvements in spatial working memory, whereas low-dose exercisers experienced decreases.
  • Both exercise groups demonstrated improvements in psychomotor speed, attention, visual memory, and spatial planning.

Conclusions:

  • Exercise augmentation demonstrates a dose-response effect on specific executive function and working memory tasks in MDD patients with partial SSRI response and cognitive complaints.
  • Certain cognitive functions, such as attention and visual memory, may improve with exercise regardless of the prescribed dose.
  • Exercise represents a promising adjunctive therapy for addressing cognitive deficits in major depressive disorder.